title: Interferon may reduce minimal residual disease of acute promyelocytic leukemia.
authors.forename: M
authors.initials: M
authors.lastname: Egyed
authors.forename: G
authors.initials: G
authors.lastname: Rumi
authors.forename: B
authors.initials: B
authors.lastname: Boros
authors.forename: P
authors.initials: P
authors.lastname: Páldi-Haris
authors.forename: J
authors.initials: J
authors.lastname: Földi
mesh_terms: D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003561:Cytarabine / Q000008:administration & dosage; D003630:Daunorubicin / Q000008:administration & dosage; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage; D007372:Interferons / Q000627:therapeutic use*; D015473:Leukemia, Promyelocytic, Acute / Q000188:drug therapy*; D018365:Neoplasm, Residual / Q000188:drug therapy*; D012008:Recurrence; D012074:Remission Induction; D014212:Tretinoin / Q000008:administration & dosage
chemical_list: D003561:Cytarabine; D014212:Tretinoin; D007372:Interferons; D015255:Idarubicin; D003630:Daunorubicin